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http://dx.doi.org/10.1016/j.ccr.2012.05.037SUMMARYInhibition of VEGF signaling leads to a proinvasive phenotype in mouse models of glioblastoma multiforme
(GBM) and in a subset of GBM patients treated with bevacizumab. Here, we demonstrate that vascular
endothelial growth factor (VEGF) directly and negatively regulates tumor cell invasion through enhanced
recruitment of the protein tyrosine phosphatase 1B (PTP1B) to a MET/VEGFR2 heterocomplex, thereby sup-
pressing HGF-dependent MET phosphorylation and tumor cell migration. Consequently, VEGF blockade
restores and increasesMET activity in GBMcells in a hypoxia-independentmanner, while inducing a program
reminiscent of epithelial-to-mesenchymal transition highlighted by a T-cadherin to N-cadherin switch and
enhanced mesenchymal features. Inhibition of MET in GBM mouse models blocks mesenchymal transition
and invasion provoked by VEGF ablation, resulting in substantial survival benefit.INTRODUCTION
Glioblastoma multiforme (GBM) are characterized by rapid and
invasive growth throughout the brain. Despite standard and
targeted therapies median overall survival of GBM patients
remains just over one year (Furnari et al., 2007). GBM are also
one of the most vascularized and edematous tumors as they
express high levels of VEGF (Ferrara et al., 2003; Sundberg
et al., 2001; van Bruggen et al., 1999). Encouragingly, bevaci-
zumab, a humanized monoclonal antibody against VEGF, has
demonstrated therapeutic benefit in many GBM patients whenSignificance
Bevacizumab has been approved for the treatment of GBM pat
for frontline therapy. Most patients initially experience beneficia
regrowth. About 20%–30% of recurrent tumors elicit an infiltr
resection unfeasible and imparts detrimental effects. The abil
genic treatment without developing more invasive tumors is th
by which VEGF ablation causes enhanced invasion. These find
VEGF and MET in GBM patients to overcome proinvasive resiused alone or in combination with irinotecan (Friedman et al.,
2009; Vredenburgh et al., 2007). This led to the accelerated
approval of bevacizumab by the U.S. Food and Drug Adminis-
tration in 2009 for use as a single agent in recurrent GBM, and its
use in the frontline setting for newly diagnosed GBM is currently
being evaluated.
Despite initial responsiveness, however, the beneficial effects
of bevacizumab are transient, and GBM inevitably progress
during anti-VEGF treatment by adapting and utilizing alternative
pathways to sustain tumor growth, all while VEGF signaling
remains inhibited (Bergers and Hanahan, 2008).ients with recurrent disease and is currently being evaluated
l effects from the treatment, but all invariably confront tumor
ating and more diffuse growth pattern that renders surgical
ity to identify GBM patients who will benefit from antiangio-
erefore pivotal. Here, we provide the molecular mechanisms
ings support combined treatment strategies targeting both
stance and prolong survival.
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VEGF Inhibits MET Activity and Tumor InvasionClinical evidence suggests that GBM relapse during anti-
VEGF therapy can present with at least two differing radio-
graphic patterns representing distinct mechanisms of evasion.
Although most GBM patients develop characteristic local re-
currences that regain the ability to induce neovascularization
as observed by increased magnetic resonance imaging (MRI)
contrast enhancement, up to 30% of GBMpatients demonstrate
a more extensive, infiltrative, and distant disease that lacks
angiogenic induction and is noncontrast enhancing but is in-
stead detectable by fluid-attenuated inversion recovery (FLAIR)
MRI (de Groot et al., 2010; Iwamoto et al., 2009; Rose and
Aghi, 2010). Whereas the incidence of invasion has been
a subject of discussion because of the current lack of a standard-
ized definition for radiographic relapse (Chamberlain, 2011;Wick
et al., 2011), the frequency of invasive nonenhancing tumors
nevertheless appears to be higher than would be expected in
patients who do not receive bevacizumab (Iwamoto et al.,
2009). This proinvasive recurrence encumbers surgical resection
of recurrent GBM and challenges further therapeutic options for
patients.
Similar to other studies usingmousemodels of GBM (de Groot
et al., 2010; Kunkel et al., 2001; Rubenstein et al., 2000), we have
observed that a more perivascular invasive phenotype, in which
tumor cells move predominantly along blood vessels deep into
the brain parenchyma, was induced when murine GBM were
unable to initiate angiogenesis, a phenomenon that predicted
the invasive relapse pattern seen in bevacizumab-treated human
GBM (Blouw et al., 2003; Du et al., 2008a; Pa`ez-Ribes et al.,
2009). The enhanced invasiveness was a result of impairing
tumor angiogenesis either through genetic ablation of key angio-
genic factors that drive VEGF-dependent neovascularization
(HIF-1a, VEGF, MMP-9, MMP-2) (Blouw et al., 2003; Du et al.,
2008a, 2008b) or by pharmacologic targeting of VEGF signaling
(Pa`ez-Ribes et al., 2009). We further revealed an unexpected link
between HGF and VEGF, in which VEGF reduced the chemo-
tactic activity of GBM cells toward HGF in vitro (Du et al.,
2008a). The HGF receptor MET, a receptor tyrosine kinase that
is frequently deregulated in many cancers and promotes prolif-
eration, scattering, invasion, survival, and angiogenesis (Birch-
meier et al., 2003; Rong et al., 1992; Trusolino et al., 2010;
Wang et al., 2001) is correlated with increased tumor invasion
and poorer survival in GBM (Abounader and Laterra, 2005;
Koochekpour et al., 1997; Lamszus et al., 1998).
Given that VEGF inhibition was a common denominator
among the various genetic knockout models and pharmacologic
treatments described above, we investigated whether VEGF
itself might act as a regulatory switch for GBM invasion through
regulating MET.
RESULTS
Intratumoral VEGF Levels Inversely Correlate with MET
Phosphorylation and Invasion of GBM Tumor Cells
To test our hypothesis that VEGF regulates the HGF/MET axis
in tumor cells, we used orthotopically implanted SV40 large
T-antigen and H-ras-transformed mouse astrocytoma cell lines
differing only in their VEGF expression levels: VEGFKO GBM,
which are genetically ablated of VEGF expression; WT-GBM,
which produce endogenous levels of VEGF; and VEGFKO-22 Cancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc.VEGF GBM, which are VEGFKO GBM cells expressing a high
level of exogenous VEGF (Figures 1A and 1B). VEGFKO tumors
were nonangiogenic and grew as extensively diffuse and inva-
sive tumor cell clusters along normal blood vessels deep into
the brain parenchyma (Figure 1A) (Blouw et al., 2003). In con-
trast, WT-GBM cells generated angiogenic tumors with locally
infiltrative tumor cells characteristic of human GBM, and
VEGFKO-VEGF cells produced highly vascular, tightly packed
tumors with smooth borders (Figure 1A). We then assessed
whether changes in MET expression and activation could
account for differences in invasive capacity. Immunohistochem-
ical staining and western blot analysis of total MET in orthotopic
murine GBM xenografts and cell lines showed abundant and
similar MET expression regardless of VEGF expression levels
(Figure 1C; Figures S1A–S1C available online). In contrast, phos-
pho-MET (P-MET) staining revealed strong positivity in invading
clusters of VEGFKO GBM, marginal staining in a few invading
tumor cells in WT-GBM, and no staining throughout VEGFKO-
VEGF GBM (Figure 1D). These observations were recapitulated
in another murine GBMmodel (NSCG), in which neural stem cells
were isolated from the subventricular zone of Ink4a/Arf deficient
mice and transduced with the constitutively active mutant
receptor EGFRvIII (Phillips et al., 2012) (Figures S1D–S1F).
Importantly, when we assessed P-MET in GBM specimens
from patients who had relapsed during bevacizumab therapy,
we observed stronger and more abundant positivity in tumors
posttreatment compared to matched pretreated samples in
7 out of 10 patients (Figures 1E and 1F). These data indicate
that loss of VEGF induces MET activation in invading tumor cells
without necessarily increasing MET expression and inferred
a mechanism distinct from that of intratumoral hypoxia induced
by anti-VEGF therapy causing transcription of hypoxia-regulated
proinvasive genes, such as Met to perpetuate invasion.
VEGF Directly and Negatively Regulates GBM Invasion
by Inhibiting MET Activation
We then askedwhether VEGF could signal directly on tumor cells
to affect MET activity and invasiveness. We first examined
whether VEGF perturbed the HGF/MET signaling pathway. To
test this, VEGFKO cells were stimulated with HGF alone or in
combination with VEGF. HGF treatment resulted in robust phos-
phorylation of MET and of FAK, which were decreased by VEGF
in a dose-dependent manner (Figure 2A). Similarly, MET and FAK
activation induced by HGF were reduced when VEGFKO cells
were incubated with VEGFKO-VEGF conditioned medium (CM)
but not VEGFKO CM (Figure 2A). Total MET expression was
unaltered by VEGF. In contrast, stimulation with increasing
concentrations of HGF in the presence of high VEGF levels
dose-dependently restored P-MET and P-FAK, supporting an
antagonistic and dynamic interplay between VEGF and HGF
on MET signaling (Figure 2A). VEGF also inhibited P-MET and
P-FAK in human GBM43 cells derived from a GBM patient
(Sarkaria et al., 2006) (Figure 2B). The antagonistic interaction
between VEGF and HGF/MET appeared specific, as neither
EGF nor PDGF suppress P-MET or P-FAK induced by HGF (Fig-
ure S2A). Treatment of GBM43 cells with the function-blocking
anti-VEGF monoclonal antibody B20 (Liang et al., 2006) abro-
gated P-MET suppression by VEGF (Figure 2C), further support-
ing a specific role for VEGF in regulating MET activation.
Figure 1. VEGF Expression Is Inversely
Correlated with Perivascular Invasion and
MET Phosphorylation
(A) Tumors from intracranial implantation of
indicated murine GBM cells were fluorescently
stained for SV40 large T-antigen and CD31 to
detect tumor cells and vasculature, respectively.
Scale bars, 200 mm.
(B–D) IHC staining for VEGF (B), total MET (C),
and phospho-MET (D) in orthotopic murine GBM.
Scale bars, 100 mm.
(E) IHC staining for phospho-MET in paired
human GBM surgical specimens before and after
bevacizumab (BV) treatment. Scale bars, 50 mm.
(F) P-MET staining score (mean ± SEM) of ten
human GBM before and after bevacizumab treat-
ment based on a composite score as described in
the Supplemental Experimental Procedures.
See also Figure S1.
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VEGF Inhibits MET Activity and Tumor InvasionWe next determined whether VEGF affected HGF-dependent
GBM cell invasion by performing a wound-healing assay. HGF-
treated VEGFKO cells closed nearly the entire wound area within
16 hr, whereas addition of exogenous VEGF significantly dimin-
ished their migration (Figure 2D). Similarly, VEGFKO-VEGF
cells exhibited reduced migratory capacity, and application of
VEGFKO-VEGF CM onto VEGFKO cells impeded cell migra-
tion (Figure 2D). Overexpression of VEGF or incubation with
VEGFKO-VEGF CM also reduced P-MET in NSCG and GBM43
cells and hindered their migration (Figures S2B–S2C; Figure 2E).
These studies demonstrate that VEGF directly impedes HGF-
dependent MET signaling and migration in murine and human
GBM cells.
VEGF Requires VEGFR2 to Inhibit MET Activation and
Cell Motility
How does VEGF block HGF/MET signaling? One might envision
that VEGF directly competes with HGF for MET binding or thatCancer Cell 22, 2VEGF antagonizes MET activity by sig-
naling through VEGF receptors on tumor
cells (Figure 3A). Congruent with reports
that a variety of tumor cells express
VEGF receptors (Lesslie et al., 2006;
Spannuth et al., 2009; Wang et al.,
2010), we found that murine and human
GBM cells express VEGFR1 and VEGFR2
(Figures 3B, S3A and, S3B) and that many
tumor cell lines representing other cancer
types for which bevacizumab has been
approved, also express VEGF receptors
at various levels (Figure S3C).
Using neutralizing antibodies against
VEGFR1 (MF1) and VEGFR2 (DC101),
we found that VEGF-dependent suppres-
sion of HGF-mediated P-MET and P-FAK
in GBM cells was abrogated by addition
of DC101 but not MF1 (Figure 3C). Con-
gruently, although VEGFKO cells treated
with VEGFKO-VEGF CM were signifi-cantly less motile, DC101 treatment restored their ability to
migrate, whereas MF1 did not (Figure 3D). We then stably
silenced VEGFR2 in VEGFKO cells by shRNA (Figure 3E).
Whereas scrambled shRNA had no effect on the negative regu-
lation of P-MET by VEGF, shVEGFR2 resulted in sustained
P-MET in the presence of VEGF (Figure 3F). Finally, addition of
VEGF to HEK293T fibroblasts, which lack VEGFR2 expression,
failed to suppress HGF-stimulated P-MET or P-FAK (Figures
3G and 3H), supporting the need for VEGFR2 and ruling out
direct competition between HGF and VEGF for MET.
We then asked whether the VEGF coreceptor neuropilin-1
(NRP-1) is involved in mediating VEGF inhibition of P-MET.
NRP-1 enhances signaling of the VEGF165 isoform on VEGFR2
but is unable to bind the VEGF121 isoform (Soker et al., 1998).
VEGFKO cells stimulated with VEGF121 were still able to diminish
HGF-stimulated P-MET (Figure 3I), and NRP-1 did not coprecipi-
tate with VEGFR2/MET (data not shown), indicating that the
inhibitory effect of VEGF is independent of NRP-1.1–35, July 10, 2012 ª2012 Elsevier Inc. 23
Figure 2. VEGF Suppresses HGF-Stimulated MET Phosphorylation and Cell Motility
(A) Western blot analysis of cell lysates frommurine VEGFKO cells stimulated with various concentrations of HGF and/or VEGF for P-MET, total MET, and P-FAK.
VEGFKO cells were also incubated with their own (KO) or VEGFKO-VEGF cells (VEGF) conditioned media (CM). a-tubulin was used for loading control.
(B) Western blot analysis of human primary GBM43 cells treated with HGF and/or VEGF for P-MET, total MET, P-FAK, and a-tubulin.
(C) Western blot analysis of human GBM43 cells treated with B20 and stimulated with HGF and/or VEGF.
(D) Wound-healing assay of HGF-stimulated VEGFKO cells or VEGFKO-VEGF cells. VEGFKO cells were treated with either exogenous VEGF or CM from
VEGFKO-VEGF cells (VEGF CM). Top, quantification of wound closure (mean ± SEM). p values compared to VEGFKO cells stimulated with HGF only. Bottom,
representative images of wounded cell monolayers. Scale bars, 150 mm.
(E) Wound-healing assay of GBM43 cells treated with exogenous VEGF, VEGF CM, and VEGFKO CM (mean ± SEM). p values compared to GBM43 cells
stimulated with HGF only.
See also Figure S2.
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VEGF Inhibits MET Activity and Tumor InvasionFinally, given the negative regulation of VEGF on MET activa-
tion, we considered whether HGF could conversely affect
VEGFR2 signaling. VEGF stimulation of GBM43 cells led to
VEGFR2 phosphorylation and weak downstream activation of
Akt and MAPK (Figure S3D), whereas HGF stimulation resulted
in substantially more potent Akt and MAPK phosphorylation.
Costimulation with HGF and VEGF did not perturb VEGFR2
phosphorylation (Figure S3D), suggesting that HGF/MET sig-
naling does not negatively regulate VEGF/VEGFR2 signaling
under these conditions.24 Cancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc.Physical Association of MET and VEGFR2
We next evaluated whether VEGFR2 and MET physically asso-
ciate with each other by performing reciprocal immunoprecipita-
tion (IP) studies. IP of primary human GBM cells expressing
detectable levels of MET and VEGFR2 with a VEGFR2 antibody
followed by immunoblotting for MET revealed a physical interac-
tion between these two endogenous proteins (Figure 4A). We
then transduced VEGFKO and GBM43 cells with HA-tagged
wild-type (WT)-VEGFR2 or a truncated VEGFR2 mutant lacking
the C-terminal 450 amino acids encompassing key kinase and
Figure 3. VEGFR2 Is Required for VEGF to Suppress HGF-Stimulated MET Phosphorylation and Cell Motility
(A) Schematic of possible ways by which VEGF can block MET activation.
(B)Western blot analysis detecting relative VEGFR2 expression in GBM43 and VEGFKO tumor cells. Humanmicrovascular endothelial cells (HMEC) were used as
a positive control.
(C) VEGFKO cells stimulated with HGF or VEGF as indicated were treated with 100 mg/ml of DC101 or 100 mg/ml of MF1 and lysates subjected to immunoblotting.
(D) Motility of VEGFKO cells incubated with VEGF CM and treated with either 100 mg/ml DC101 or MF1 was assessed in the wound-healing assay (mean ± SEM).
(E) Western blot analysis showing stable knockdown of VEGFR2 in VEGFKO cells transduced with VEGFR2 shRNA (shVR2). Parental control cells (Ctl) and
a scrambled shRNA sequence (Scr) are also shown. HMEC were used as a positive control.
(F) Parental VEGFKO cells or VEGFKO cells transduced with scrambled shRNA or shRNA targeting VEGFR2 were stimulated with HGF and/or VEGF and
subjected to immunoblotting as indicated.
(G) RT-PCR and western blot analyses for VEGFR2 and MET expression in HEK293T fibroblasts. HMEC served as positive control for VEGFR2 expression.
L19 and a-tubulin were loading controls for RT-PCR and western blot, respectively.
(H) HEK293T cells stimulated with HGF and indicated concentrations of VEGF were subjected to western blot analysis as indicated.
(I) Western blot analysis of VEGFKO cells stimulated with HGF or VEGF121 as indicated.
See also Figure S3.
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Figure 4. MET and VEGFR2 Associate in a Heterocomplex
(A) Coimmunoprecipitation (IP) of endogenous VEGFR and MET in two primary human GBM cultures (SF7796 and SF8161) as visualized by IP of VEGFR2
followed by immunoblotting for VEGFR2 and MET. Whole-cell lysates from HMEC and human primary GBM43 cells overexpressing VEGFR2 by adenoviral
transduction (GBM43 WT-VR2) were run alongside as positive controls.
(B and C) Murine VEGFKO cells (B) or human GBM43 cells (C) transduced by adenovirus to overexpress HA-tagged WT-VEGFR2 or D450C-VEGFR2 with or
without stimulation of HGF or VEGF as indicated were lysed and immunoprecipitated using indicated antibodies, and the immunoprecipitates were then im-
munoblotted as indicated.
(D and E) Representative images of PLA in murine VEGFKO (D) or human GBM43 (E) cells expressing WT-VEGFR2 or D450C-VEGFR2 after treatment with the
indicated growth factors. Red spots are regions of signal amplification denoting VEGFR2 and MET interaction. Cytoskeletal staining (FITC-phalloidin) is green,
and nuclear stain (DAPI) is blue. Scale bars, 20 mm.
(F and G) Quantification of PLA signals in murine VEGFKO (F) and human GBM43 (G) cells transduced with WT-VEGFR2 (mean ± SEM).
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VEGF Inhibits MET Activity and Tumor Invasioneffector domains (VEGFR2-D450C). IP of these cells with a MET
antibody or a HA-Tag antibody revealed an interaction of MET
with WT-VEGFR2 but not with VEGFR2-D450C (Figures 4B
and 4C), indicating that the C-terminal region of VEGFR2 is
required for MET association. The physical association between
MET and VEGFR2 was observed independent of stimulation of
either receptor with its cognate ligand, but P-MET coprecipitated
only when cells were stimulated with HGF, and addition of VEGF
suppressed HGF-stimulated P-MET only when cells were trans-
ducedwithWT-VEGR2, not VEGFR2-D450C (Figures 4B and 4C).26 Cancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc.Similar to the IP studies, proximity ligation assay (PLA) (So¨der-
berg et al., 2008) demonstrated an interaction between MET and
WT-VEGFR2, but not with VEGFR2-D450C, in VEGFKO and
GBM43 cells irrespective of stimulation with either ligand (Fig-
ures 4D and 4E). However, when GBM cells expressing WT-
VEGFR2 were costimulated with HGF and VEGF, the number
of PLA spots per cell was slightly reduced but the size of these
spots increased (Figures 4D–4G). These results suggest that
additional proteins might associate with and redistribute the
complex when both ligands are present.
Figure 5. VEGF Signaling Increases PTP1B Recruitment to MET
(A) Control GBM43 cells, GBM43 cells treated with sodium orthovanadate (Na3VO4) for 30 min, or GBM43 cells transfected with PTP1B siRNA were stimulated
with HGF, VEGF, or both ligands at the concentrations indicated and lysates analyzed by western blot for P-MET, total MET, and PTP1B.
(B) GBM43 cells stimulated with HGF and/or VEGF were crosslinked with the membrane-permeable and cleavable crosslinker DSP and 250 mg of each lysate
immunoprecipitated with an anti-MET antibody, followed by immunoblotting for MET and PTP1B. GBM43 whole-cell lysate served as a positive control for
analysis of the immunoprecipitates.
(C) Representative images of immunofluorescent staining of GBM43 cells treated with HGF and/or VEGF for MET (red), EEA-1 (green), and DAPI (blue). ROI:
higher magnification of the indicated area. Arrows indicate colocalization of MET and EEA-1-positive vesicles. Scale bar = 10 mm.
(D) Quantification of colocalization between MET and EEA-1 staining (mean ± SEM).
See also Figure S4.
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VEGF Inhibits MET Activity and Tumor InvasionVEGF Enhances Recruitment of the Tyrosine
Phosphatase PTP1B to MET and Facilitates
Downregulation of HGF-Induced MET Phosphorylation
Several mechanisms for attenuation of MET signaling have been
described, including internalization and degradation, as well as
dephosphorylation by specific tyrosine phosphatases (Abella
et al., 2005; Hammond et al., 2003; Sangwan et al., 2008). We
found that VEGF stimulation did not decrease total MET over
time (Figures 2A, 2B, and S4A–S4C) or enhance the phosphory-
lation of Ser985 of MET (data not shown), a negative regulatory
site that suppresses MET tyrosine phosphorylation (Gandino
et al., 1994). In contrast, treatment of GBM43 cells with the tyro-
sine phosphatase inhibitor sodium orthovanadate abrogated the
suppressive effect of VEGF on P-MET (Figure 5A), indicating the
involvement of a tyrosine phosphatase. Among the various tyro-
sine phosphatases known to modulate MET activity is the non-
receptor protein tyrosine phosphatase 1B (PTP1B), which candirectly dephosphorylate various RTKs including MET and
VEGFR2 (Nakamura et al., 2008; Sangwan et al., 2008). Knock-
down of PTP1B in GBM43 cells abolished downregulation of
P-MET by VEGF (Figure 5A), supporting a role for PTP1B
in VEGF-dependent suppression of P-MET. We then asked
whether the extent of interaction between PTP1B and MET
was modulated in the presence of VEGF. Co-IP studies revealed
low levels of PTP1B/MET interaction in untreated and VEGF-
stimulated cells (Figure 5B). As expected, PTP1B/MET associa-
tion was elevated when cells were stimulated with HGF and was
further increased when cells were costimulated with HGF and
VEGF (Figure 5B). These data indicate that VEGF enhances
recruitment of PTP1B to MET and facilitates dephosphorylation
of HGF-induced P-MET.
UponHGF stimulation, MET enters the endocytic pathway and
is either targeted for lysosomal degradation or recycled back to
the cell surface (Abella et al., 2005; Hammond et al., 2003). WeCancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc. 27
Figure 6. MET Knockdown Blocks Tumor Invasion and Promotes Survival of VEGF-Deficient Tumors
(A) Immunoblot analysis of MET expression in VEGFKO cells stably transduced with two independent shRNAs targeting MET. Parental VEGFKO cells (Ctl) and
VEGFKO cells transduced with a scrambled shRNA (Scr) are also shown.
(B) Representative images (left) and quantification (right, mean ± SEM) of a wound-healing assay comparing migration of VEGFKO-shMET1 cells to VEGFKO
cells. Dashed white lines indicate edge of wound. Scale bar, 100 mm.
(C and D) Immunohistochemical staining of intracranial VEGFKO, VEGFKO-scrambled, and VEGFKO-shMET1 tumors with SV40 large T-antigen (red) and
CD31 (green) (C), or with SV40 large T-antigen (red) and DAPI (blue) (D), to visualize tumor cells and vasculature, respectively. Yellow boxes in (D)
(scale bar, 1 mm) represent the region of magnification shown in (C) (scale bar, 200 mm). Images are representative of time-matched samples 23 days post-
implantation.
(E) Quantification of total invasion from the primary tumor mass in VEGFKO or VEGFKO-shMET1 tumors over various time points (mean ± SEM). The number of
mice analyzed for each condition and time point is indicated.
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VEGF Inhibits MET Activity and Tumor Invasionthus considered whether VEGF could enhance MET dephos-
phorylation by altering MET internalization and trafficking
kinetics. To this end, we tracked MET colocalization with estab-
lished endosomal markers indicative of different stages of
trafficking (Stenmark, 2009). In serum-starved, unstimulated, or
VEGF-treated GBM43 cells, MET was predominantly localized
to the plasma membrane, whereas HGF stimulation caused
MET internalization into EEA-1 positive endosomes (Figures 5C
and 5D). Costimulation of GBM43 cells with VEGF and HGF
provided a modest but not statistically significant increase in
MET/EEA-1 colocalization (Figure 5D). Similar results were
observed in VEGFKO cells (data not shown). We also studied
colocalization of MET with GFP-fusion constructs of the early
endosome markers Rab5 and Rab4, the late endosome marker
Rab7, and the recycling endosome marker Rab11. Under the
same stimulation conditions and time frame that revealed
optimal VEGF-induced suppression of P-MET, we found MET
predominantly in early endosomes upon stimulation with HGF
irrespective of VEGF (Figures S4D–S4E). These results reveal
that VEGF enhances recruitment of PTP1B to the VEGFR2/
MET complex to facilitate MET dephosphorylation but does
not alter endocytosis and trafficking.
MET Knockdown Blocks Invasiveness during VEGF
Ablation and Prolongs Survival
If HGF/MET signaling is indeed a key mediator of GBMmigration
and invasion, MET inhibition should suppress tumor invasion
provoked by VEGF ablation. Thus, we stably knocked down
MET expression in VEGFKO cells using two independent
shRNAs (VEGFKO-shMET1 and VEGFKO-shMET2) by 85%
and 60%, respectively (Figure 6A). VEGFKO-shMET1 cells dis-
played significantly impaired in vitro motility (Figure 6B) and
proliferation (Figure S5A). Most importantly, VEGFKO-shMET1
tumors growing intracranially in mice were substantially less
invasive and grew as a solid mass even at end-stage (Figures
S5B and S5C) in contrast to the extensive perivascular invasive
phenotype of time-matched VEGFKO parental and scrambled-
shRNA tumors (Figures 6C and 6D). Both the total number of
invading cell clusters and invasion distance were considerably
lower in VEGFKO-shMET1 tumors compared to VEGFKO tumors
(Figures 6E and S5D–S5F). VEGFKO-shMET1 tumors also dis-
played lower in vivo proliferation (Figure 6F) and reduced
vascular density (Figure 6G) compared to VEGFKO, indicating
the pleiotrophic effects of MET signaling. These effects led to a
3-fold prolongation of survival compared to WT-GBM, sur-
passing the survival benefit observed in VEGFKO over WT-
GBM (Figure 6H). Notably, because the silencing effect in
VEGFKO-shMET2 was less effective, MET-positive tumor cells
eventually emerged over time, leading to invasive progression
(Figures S5A and S5H–S5J) and reduced survival benefit over
control tumors (Figure S5G). These results underscore MET as
a critical driver of GBM invasion and strongly encourage
combined anti-VEGF and anti-MET therapy for GBM patients.(F and G) Proliferation (F) and vessel density (G) in orthotopic VEGFKO and VEGFK
histone H3 and CD31 staining, respectively (mean ± SEM).
(H) Kaplan-Meier survival curves of mice intracranially implanted with WT-GBM
VEGFKO-shMET1 versus VEGFKO-scramble.
See also Figure S5.HGF/MET Signaling Induces an EMT-like Mesenchymal
Phenotype in GBM
Knocking down MET in VEGFKO cells also changed their
spindle-like, fibroblastic morphology toward one in which they
clustered together into islands with minimal astrocytic pro-
cesses (Figure 7A) reminiscent of epithelial cells undergoing
a mesenchymal-to-epithelial transition (Kalluri and Weinberg,
2009; Thiery et al., 2009). Several recent studies have raised
the notion that a mesenchymal gene expression signature is
associated with poorer prognosis in GBM patients (Phillips
et al., 2006; Tso et al., 2006; Verhaak et al., 2010). Therefore,
we speculated that VEGF inhibition, and hence MET activation
in GBM, may induce or enhance a switch to a more mesen-
chymal and aggressive state, analogous to the classical
epithelial-to-mesenchymal transition (EMT) described in epithe-
lial cells. Indeed, we found that VEGFKO cells gradually upregu-
lated the EMT markers Snail and N-cadherin but suppressed
T-cadherin over a 24 hr time course of HGF stimulation (Fig-
ure 7B). These effects were dependent on MET, as HGF-stimu-
lated VEGFKO-shMET1 cells were unable to induce Snail and
N-cadherin or downregulate T-cadherin (Figure 7B). Consistent
with a report that T-cadherin promotes glioma cell growth arrest
(Huang et al., 2003), T-cadherin expression was higher in less
invasive and slower growing VEGFKO-shMET1 cells than in
VEGFKO cells (Figure 7C). Upregulation of N-cadherin was not
associated with suppression of E-cadherin as VEGFKO cells
lack E-cadherin expression (data not shown). Importantly,
when HGF-induced P-MET and P-FAK was tempered by VEGF
in VEGFKO cells, N-cadherin was correspondingly suppressed
(Figure 7D).
In vivo, N-cadherin staining was observed in the centers of
VEGFKO tumors but was substantially stronger in invading cells
at the tumor periphery in correlation with strong P-MET staining
found only in invading cells (Figure 7E). Conversely, VEGFKO
tumor centers were weakly positive for T-cadherin, and the
invading cells were negative (Figure 7E). VEGFKO-shMET1
tumors had smooth borders and were positive for T-cadherin,
whereas N-cadherin was weak in the tumor center and absent
at the rim (Figure 7E).
We next tested whether increased MET activation due to
VEGF ablation could indeed induce a more mesenchymal and
aggressive phenotype. We pharmacologically inhibited VEGF
and angiogenesis in orthotopic WT-GBM tumors with the anti-
VEGF antibody B20, which imparted a significant survival benefit
mirroring that which was observed in VEGFKO tumors (Fig-
ure S6A). As expected, treatment of WT-GBM-bearing mice
with B20 increased cell invasion at the tumor periphery com-
pared to control tumors (Figure 7F; Figure S6B). These invading
cells were strongly positive for P-MET and correspondingly ex-
hibited upregulation of N-cadherin and downregulation of
T-cadherin (Figure 7F). In contrast, P-MET staining in control
WT-GBM tumors was restricted to only a few infiltrating cells at
the tumor periphery, similar to their limited pattern of N-cadherinO-shMET1 tumors 23 days after tumor inoculation as determined by phospho-
, VEGFKO, VEGFKO-scrambled, and VEGFKO-shMET1 cells. p = 0.007 for
Cancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc. 29
Figure 7. HGF/MET Signaling Induces an EMT-like Transition in GBM
(A) Representative phase contrast microscopy images of VEGFKO and VEGFKO-shMET1 cells. Scale bars, 100 mm.
(B) Immunoblot analysis of VEGFKO or VEGFKO-shMET1 cells stimulated with HGF for the indicated times for P-Met, Snail, N-cadherin, and T-cadherin
expression.
(C) Immunoblot analysis of T-cadherin expression in VEGFKO-shMET1 cells and parental VEGFKO cells.
(D) Immunoblot analysis of VEGFKO cell lysates 6 hr after stimulation with HGF or indicated concentrations of VEGF.
(E and F) Immunohistochemical staining of intracranial mouse GBMs for P-MET, N-cadherin, and T-cadherin (brown). Sections were counterstained with
hematoxylin (blue). Staining at the center of the main tumor mass or at the tumor rim is shown as indicated. (E) Representative images of time-matched (day 27)
VEGFKO and VEGFKO-shMET1 tumors. Dashed lines indicate the smooth border of VEGFKO-shMET1 tumors. (F) Mice bearing orthotopic WT-GBM were
treatedwith B20 or vehicle beginning 3 days after tumor implantation. Representative staining of tumors frommice sacrificed 16 days after tumor implantation are
shown. Tumor cells were visualized by staining for SV40 Tag (top). Scale bars, 50 mm.
See also Figure S6.
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Figure 8. Bevacizumab-Resistant Human GBM Exhibit Increased P-MET and Expression of Mesenchymal Markers
(A andB)PairedhumanGBMsamples obtainedbefore and after treatmentwith bevacizumab (BV)were immunohistochemically stained for P-METandN-cadherin
(brown) and counterstained with hematoxylin (blue) (A). Representative images of staining from the same area of serial sections are shown. Tissues were also
fluorescently costained for the mesenchymal markers vimentin (green) and CD44 (red) and nuclei visualized with DAPI (blue) (A and B). Scale bars, 50 mm.
(C) Staining scores (mean ± SEM) of the mesenchymal markers vimentin, CD44, and YKL-40 in paired human GBM specimens before and after BV. Each sample
was scored on a scale of 0–3 and the number of paired patient samples analyzed for each marker is indicated.
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VEGF Inhibits MET Activity and Tumor Invasionexpression (Figure 7F). T-cadherin was strongly expressed in
many cells but not uniformly positive, with the frequency of posi-
tive cells diminishing toward the tumor edge (Figure 7F). Overall,
MET phosphorylation was associated with tumor cell invasion,
increased N-cadherin, and decreased T-cadherin expression.
Similar results were observed when mice bearing WT-GBM
tumors were treated with the broad-spectrumRTK inhibitor suni-
tinib, which also targets the VEGF pathway (Figure S6C). These
results indicate that MET activation induces a mesenchymal
transformation inGBMunderscored by a T- to N-cadherin switch
distinct from the classical E- to N-cadherin switch.
Bevacizumab-Resistant Human GBM Exhibit Increased
MET Activation and Expression of Mesenchymal
Markers
To determine whether mesenchymal markers are elevated in
correlation with increased P-MET-positive invasive cell clusters
in GBM patients after bevacizumab treatment, we examined
our paired pre- and postbevacizumab treatment patient tumor
specimens. Of seven relapsed tumors showing increased
P-MET staining after treatment (Figures 1E and 1F), six ex-
hibited a corresponding increase in the extent and intensity of
N-cadherin staining (Figure 8A). Of these six tumors, five showed
upregulation of the mesenchymal marker vimentin with three ofthem further displaying higher levels of CD44, a mesenchymal
stem cell marker associated with GBM (Tso et al., 2006) (Figures
8A and 8B). In total, 8 of 9 analyzed tumor pairs demonstrated an
increase in vimentin after bevacizumab treatment, while 6 of 9
exhibited increased CD44 (Figures 8A and 8B). Expression of
YKL-40, a marker for the mesenchymal subtype of GBMs
(Phillips et al., 2006), was also upregulated after bevacizumab
treatment in 3 of 5 tumor pairs examined (Figure 8C). The
mean staining intensities for vimentin, CD44, and YKL-40 were
significantly higher in bevacizumab-resistant tumors than in
paired pretreatment specimens (Figure 8C). These results
suggest that human GBM treated with targeted VEGF therapy
may progress by switching to a more mesenchymal phenotype
involving upregulation of MET activity and expression of key
mesenchymal genes and markers.
DISCUSSION
VEGF has been thought to act predominantly on the vascula-
ture, given that its receptors are prevalent in endothelial cells
and that deletion of either VEGF or VEGFR2 results in early
embryonic lethality because of impaired hematopoietic and
endothelial cell development (Ferrara, 2001; Olsson et al.,
2006). The main signaling circuit of VEGF is thought to beCancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc. 31
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including proliferation, migration, and vessel formation (Ferrara
et al., 2003; Olsson et al., 2006; Shibuya, 2006). Emerging
from these observations was the rationale to target the VEGF/
VEGFR2 signaling pathway as an antiangiogenic strategy,
a notion that has subsequently been supported by a wealth of
preclinical data as well as clinical results (Crawford and Ferrara,
2009; Jain, 2008). However, more rigorous expression analyses
recently have revealed the expression of VEGF receptors,
specifically VEGFR2, on nonendothelial cells, including hemato-
poietic cells, megakaryocytes, pancreatic duct cells, pericytes,
and even tumor cells of various origins (Dallas et al., 2007;
Greenberg et al., 2008; Hamerlik et al., 2012; Matsumoto and
Claesson-Welsh, 2001; Silva et al., 2011). This suggests that
VEGF likely has additional effects on tumors besides promoting
neovascularization.
VEGF Signaling in Tumor Cells
In this study we identified an autocrine VEGF/VEGFR2 loop
in GBM cells that negatively affects MET activity through re-
cruitment of the phosphatase PTP1B to a VEGFR2/MET hetero-
complex. Indeed, evidence for crosstalk between VEGFR2 or
MET and other receptor tyrosine kinases (RTKs) is growing.
Most recently, VEGFR2 expression was identified on pericytes,
where it physically associates with and suppresses PDGFRb
signaling, consequently ablating pericyte coverage of nascent
vascular sprouts (Greenberg et al., 2008). These results are anal-
ogous to our own, conveying VEGF/VEGFR2 as a negative regu-
lator of other RTKs by blocking their activation through direct
interaction.
Both MET and VEGFR2 have been found to interact with
a variety of other coreceptors and surface molecules as well
(Birchmeier et al., 2003; Koch et al., 2011; Li et al., 2008; Truso-
lino et al., 2010). Notably, VEGFR2 and MET are each able to
associate with neuropilin-1 (NRP-1), a receptor for class 3
semaphorins that is thought to enhance signaling of these two
RTKs (Hu et al., 2007; Soker et al., 1998). However, our results
suggest that NRP-1 is not a coreceptor of the VEGFR2/MET
complex, which might not be unexpected because the hetero-
complex blocks MET signaling, but we cannot rule out the asso-
ciation of other coreceptors within this complex.
The aforementioned results suggest that VEGF levels act as
a sensor for the vascular and tumor cell compartments in part
by sending signals through VEGFR2 complexes on endothelial
cells and at least two distinct VEGFR2/RTK heterocomplexes
(i.e., VEGFR2/MET on tumor cells and VEGFR2/PDGRb on
pericytes). One can speculate that the distinct associations of
VEGFR2 with other RTKs might reflect a level of regulation by
which VEGF can positively or negatively signal in different cell
types. Although high levels of VEGF facilitate angiogenesis and
thereby enable tumor cells to expand, low levels of VEGF lead
to a reduction in tumor vessel growth and protection of remain-
ing vessels and concomitantly promote signals for GBM cells to
move away from these undesirable conditions.
Microenvironmental Regulation of MET Activity
during Anti-VEGF Therapy
MET transcription is induced by the hypoxia-inducible factor
HIF-1a in some tumor cells, including GBM (Eckerich et al.,32 Cancer Cell 22, 21–35, July 10, 2012 ª2012 Elsevier Inc.2007; Pennacchietti et al., 2003), andMET expression was found
to be upregulated in a subset of bevacizumab-treated patients
(Rose and Aghi, 2010). Because reduction in vessel density
causes low oxygen tension, it is conceivable that increased
METactivity in response to anti-VEGF therapymight be regulated
by hypoxia. However, we observed MET activity primarily at the
invasive edges of tumors that are not hypoxic, rather than within
the tumor mass, where low oxygen tension is more severe. We
also observed that HIF1a-KO murine GBM were much more
invasive than wild-type tumors, concomitant with high P-MET
in the invasive areas (Blouw et al., 2003; Du et al., 2008a). Hence,
these results demonstrate that the invasive phenotype cannot
be exclusively driven by inadequate oxygen or nutrient supply.
Although we observed VEGFR2/MET complexes in the
absence of ligand, the heterodimers appeared to coalesce into
larger clusters only upon costimulation with HGF and VEGF, sug-
gesting that additional proteins might further associate with the
complex in the presence of both ligands. Indeed, we found
that VEGF enhanced the recruitment of PTP1B to the VEGFR2/
MET complex, which upon HGF stimulation, facilitated MET
dephosphorylation. In addition to directly dephosphorylating
ligand-stimulated RTK substrates, such as MET, VEGFR2,
EGFR, insulin receptor, and PDGFR (Galic et al., 2005; Haj et al.,
2003; Nakamura et al., 2008; Sangwan et al., 2008), PTP1B also
regulates their endosomal trafficking and internalization into
multivesicular bodies (Eden et al., 2010; Sangwan et al., 2011;
Stuible and Tremblay, 2010). In the context of VEGF-driven
suppression of MET activation, however, we observed no sig-
nificant differences in MET endocytosis with VEGF treatment,
suggesting that the principal role of PTP1B in this mechanism
is to directly dephosphorylate MET. We found that MET was
predominantly localized to early endosomes when cells were
stimulated with HGF with or without VEGF. Because MET can
continue to signal as it progresses along the endocytic pathway
(Abella et al., 2005), VEGF-enhanced recruitment and activity of
PTP1B may likely be important in maintaining suppression of
P-MET in the endosomal compartments. Accordingly, lowering
VEGF levels and/or increasing HGF levels would lead to rapid
MET reactivation and enhanced tumor cell invasiveness.
VEGF Regulates HGF-Induced EMT-like Traits
in GBM cells
Interestingly, activation of MET by genetic and pharmacologic
VEGF inhibition increased invasion concomitant with induction
of mesenchymal features. Similar to a recent report that MET
signaling induces Snail (Grotegut et al., 2006), we observed Snail
and N-cadherin upregulation in GBM cells, which was surpris-
ingly associated with T-cadherin downregulation. The latter
observation implies an alternative cadherin switch distinct from
the classical E-cadherin to N-cadherin switch in epithelial cells
(Kalluri and Weinberg, 2009). T-cadherin is an atypical member
of the cadherin family devoid of a transmembrane domain but
anchored to the surface of the plasma membrane via a glycosyl-
phosphatidylinositol anchor (Andreeva and Kutuzov, 2010).
Although it is expressed in many tumor vessels, downregula-
tion of T-cadherin is observed in a variety of cancer cells and
associated with a poorer prognosis (Andreeva and Kutuzov,
2010). In GBM cells, overexpression of T-cadherin suppresses
proliferation and migration (Huang et al., 2003), consistent with
Cancer Cell
VEGF Inhibits MET Activity and Tumor Invasionour observation that T-cadherin expression was higher in cir-
cumscribed, minimally invasive VEGFKO-shMET GBM but
absent in invasive GBM with high MET activity. In addition we
found that HGF stimulation suppressed T-cadherin within 6 hr,
suggesting that HGF-induced EMT signals affect T-cadherin
transcription. Further supporting a role for T-cadherin in an
EMT-like acquisition in GBM is a recent report demonstrating
that Zeb-1 suppresses T-cadherin and increases invasion in
gallbladder cancer (Adachi et al., 2009).
Clinical Implication
These studies together suggest that one might be able to select
GBM patients upfront who may likely develop a proinvasive
recurrence during bevacizumab treatment by evaluating MET
and VEGFR2 expression in the tumor. This is particularly instru-
mental in light of the fact that GBM are heterogeneous by nature
and can be classified into four distinct molecular subtypes
(Phillips et al., 2006; Verhaak et al., 2010). Moreover, our results
suggest that patients whose GBM are positive for both MET and
VEGFR2might benefit from treatment modalities that block both
VEGF and HGF signaling. As we found VEGFR2 and MET
expression on various tumor cell types besides GBM, combined
VEGF and MET inhibition might also be useful in other cancer
types as recently shown (Sennino et al., 2012). Finally, although
HGF/MET is a major signaling node in promoting invasion, it is
likely that other proinvasive circuits are also involved in GBM
invasion during the course of anti-VEGF therapy or induced
when MET is blocked. It will be important to elucidate whether
these pathways are also linked to VEGF.
EXPERIMENTAL PROCEDURES
Cell Culture and Reagents
Generation of murine WT-GBM and VEGFKO GBM has been previously
described (Blouw et al., 2003). NSCGs were isolated from high-grade murine
gliomas generated by transplantation of adult Ink4/Arf/ neural stem cells
expressing a constitutively active mutant of human EGFR, EGFRvIII (Phillips
et al., 2012). Human GBM43 cells, which are primary cell cultures of patient-
derived GBM specimens serially passaged as subcutaneous tumors in mice,
have been previously described (Sarkaria et al., 2006). The primary human
GBM cultures SF7996 and SF8161 were derived from freshly resected tumor
specimens and expanded as glioma neural stem cell lines (Pollard et al., 2009).
HEK293T fibroblast and BV-2 microglial cells were purchased from the
American Type Culture Collection. HMEC cells have been previously
described (Ades et al., 1992; Song et al., 2005). Overexpression and knock-
down constructs are described in the Supplemental Experimental Procedures.
Human GBM Specimens
Weanalyzed paired sets of surgical specimens from ten patients with recurrent
glioblastoma treated with bevacizumab at the University of California, San
Francisco (UCSF), who demonstrated initial response but recurred while on
therapy. Formalin-fixed and paraffin-embedded tumor specimens were
collected during surgery from consenting patients, assigned a deidentifying
number, and provided by the UCSF Brain Tumor Research Center Tissue
Bank in accordance with a protocol approved by the UCSF Committee on
Human Research. Patients were selected based on availability of paired tumor
specimens from recurrent tumor before and after bevacizumab treatment.
Immunohistochemistry on human tissues was performed as described in the
Supplemental Experimental Procedures.
Animal Studies
Six- to eight-week-old FvBN Rag1ko mice were intracranially implanted with
2.5 ml of 1 3 105 murine WT-GBM, VEGFKO, VEGFKO-VEGF, VEGFKO-scramble, VEGFKO-shMET1 or 2, NSCG, NSCG-VEGF, or human GBM43
tumor cells as described previously (Blouw et al., 2003; Du et al., 2008a).
Mice bearing WT-GBMs were treated with 5 mg/kg B20 (kindly provided by
Genentech, South San Francisco, CA, USA) in PBS twice weekly by intraper-
itoneal injection beginning 3 days after tumor implantation until moribund.
Sunitinib was administered to WT-GBM bearing mice at 40 mg/kg daily by
oral gavage starting 4 days after tumor injection until moribund. Mice were
sacrificed when they developed side effects of tumor burden, such as weight
loss and lateral recumbency, or at predefined time points for comparative
analysis. Tumors were isolated from the brain and prepared for immunohisto-
chemical staining, flow cytometric analyses, or protein and RNA isolation as
described in the Supplemental Experimental Procedures. All experiments
involving animals in this study were reviewed and approved by the Institutional
Animal Care and Use Committee at UCSF.
For further experimental details, see the Supplemental Experimental
Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, Supplemental Experimental
Procedures, and Supplemental References and can be found with this article
online at http://dx.doi.org/10.1016/j.ccr.2012.05.037.
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